Nimbolide (10 mg/kg, i.v., daily, 7 days) inhibits glioblastoma multiforme tumor growth in U87EGFRvⅢ xenografted mouse model[2].
Nimbolide (5 mg/kg, 20 mg/kg; i.p.; daily, 10 days), inhibits tumor growth in HCT-116-derived xenograft mouse, reduces the expression of proteins involved in invasion, metastasis, and angiogenesis (MMP-9, CXCR4, ICAM-1, and VEGF)[5].
| Animal Model: | HCT-116-derived xenograft mouse[5] |
| Dosage: | 5 mg/kg, 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), daily, 10 days |
| Result: | Suppressed tumor growth in nude mice at a dose as low as 5 mg/kg.
Reduced tumor growth by almost 90% on day 10 at a dose as low as 20 mg/kg.
Didn’t affect the body weight of mice.
|
